NCT02000219View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 19, 2014

Primary Completion Date

January 29, 2020

Study Completion Date

January 29, 2020

Conditions
Primary Hyperoxaluria
Interventions
BIOLOGICAL

Oxalobacter formigenes

The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.

Trial Locations (1)

DE-53113

Universitätsklinikum Bonn, Department of Paediatric Nephrology, Bonn

Sponsors

Lead Sponsor

OxThera
All Listed Sponsors
collaborator

FP7-SME-2013 Research for the benefit of SMEs program

UNKNOWN

lead

OxThera

INDUSTRY

NCT02000219 - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis | Biotech Hunter | Biotech Hunter